|
|||||||||||||||||||||||||||||||||||||||||||||||||
Dr Abdul Ghaffar |
BACTERIOLOGY | IMMUNOLOGY | MYCOLOGY | PARASITOLOGY | VIROLOGY | ||||||||||||||||||||||||||||||||||||||||||||
COMPLEMENT |
|||||||||||||||||||||||||||||||||||||||||||||||||
READING: Roitt et al. Immunology (5th ed.),
chapter 4.
Double click on any word to
obtain a definition |
|||||||||||||||||||||||||||||||||||||||||||||||||
TEACHING OBJECTIVES Understand different pathways of C activation Know the enzymatic and non-enzymatic mechanisms of complement activation Know the biological properties of complement activation products Know the significance of C system in host resistance, inflammation and damage to self
Understand the mechanisms of regulating complement
activation and it products |
Proteins of the Complement System Complement system is composed of more than 25 different proteins (Table 1) produced by different tissues and cells including hepatocytes, macrophages and gut epithelial cells. These proteins are activated by a variety of agents and their activation proceeds in a cascade fashion leading to lysis. Consequently, an absence of one of the components in the pathway can disrupt the cascade and terminate the reaction.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Pathways of complement
activation Classical pathway |
|||||||||||||||||||||||||||||||||||||||||||||||||
MOVIE |
|||||||||||||||||||||||||||||||||||||||||||||||||
Binding of C1qrs (a calcium-dependent complex), present in normal serum, to Ag-Ab complexes results in autocatalysis of C1r. The altered C1r cleaves C1s and this cleaved C1s becomes an enzyme (C4-C2 convertase) capable of cleaving both C4 and C2. C4 and C2 activation (generation of C3
convertase) C3 activation (generation of C5 convertase)
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Activation of C3 by the classical pathway
Figure 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Figure 2 Lectin-initiated pathway | LECTIN PATHWAY
C4 activation can be achieved without antibody and C1 participation by the lectin pathway (Figure 2). This pathway is initiated by three proteins: a mannan-binding lectin (MBL), also known as mannan-binding protein (MBP) which interacts with two mannan-binding lectin-associated serine proteases (MASP and MADSP2), analogous to C1r and C1s. This interaction generates a complex analogous to C1qrs and leads to antibody -independent activation of the classical pathway. C1q can also bind to a number of agents including some retroviruses, mycoplasma, poly-inosinic acid and aggregated IgG, and initiate the classical pathway.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Figure 3 Spontaneous activation of C3 (C3 tick-over) | Alternative Pathway
Alternative pathway begins with the activation of C3 and requires Factors B and D and Mg++ cation, all present in normal serum.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Figure 4 Regulation of activated C3 by Cr1 |
Normal regulation of C3 convertase |
||||||||||||||||||||||||||||||||||||||||||||||||
Figure 5 Regulation of activated C3 by Daf |
Another serum protein, factor H, can displace factor B and bind to C3b. Binding of factor H makes C3b more susceptible to factor I (see figure 4). C3 convertase generated by the classical pathway is regulated also in a similar manner by DAF, Cr1 and Factor I. The only difference is that C4b-binding protein (C4b-BP, not factor H) makes it susceptible to Factor I. A genetic deficiency of factor I (or factor H) leads to uncontrolled C3 activation and is a major cause of inherited C3 deficiency. |
||||||||||||||||||||||||||||||||||||||||||||||||
Figure 6 Stabilization of C3 convertase |
Certain bacteria or their products (peptidoglycan, polysaccharides, etc.), provide a protected (activator) surface for C3b. Thus, C3b bound to such a surface is relatively resistant to the action of factor I (Figure 6). Even membrane bound C3bBb dissociates fairly rapidly. However, binding of another protein, properdin, further stabilizes this complex. It is for this reason, the alternative pathway is also called the properdin pathway. Generation of C5 convertase The alternative pathway provides a means of non-specific resistance against infection without the participation of antibodies and hence provides a first line of defense against a number of infectious agents. Many gram negative and some gram positive bacteria, certain viruses, parasites, heterologous red cells, aggregated immunoglobulins (particularly, IgA) and some other proteins (e.g. proteases, clotting pathway products) can activate the alternative pathway. One protein, cobra venom factor (CVF), has been extensively studied for its ability to activate this pathway.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Figure 7 The lytic pathway |
LYTIC Pathway
The lytic (membrane attack) pathway involves the C5-9 components. C5 convertase generated by the classical or alternative pathway cleaves C5 into C5a and C5b. C5b binds C6 and subsequently C7 to yield a hydrophobic C5b67 complex which attaches quickly to the plasma membrane (Figure 7). Subsequently, C8 binds to this complex and causes the insertion of several C9 molecules. bind to this complex and lead to formation of a hole in the membrane resulting in cell lysis. The lysis of target cell by C5b6789 complex is nonenzymatic and is believed to be due to a physical change in the plasma membrane. C5b67 can bind indiscriminately to any cell membrane leading to cell lysis. Such an indiscriminate damage to by-standing cells is prevented by protein S (vitronectin) which binds to C5b67 complex and blocks its indiscriminate binding to cells other than the primary target.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Figure 8 Regulation of C1rs (C4 convertase) by C1-INH |
Biologically active products of Complement activation Activation of complement results in the production of several biologically active molecules which contribute to resistance, anaphylaxis and inflammation.
Kinin production |
||||||||||||||||||||||||||||||||||||||||||||||||
WEB RESOURCES |
Anaphylotoxins Chemotactic Factors Opsonins Other Biologically active products of
C activation In summary, the complement system takes part in both specific and non-specific resistance and generates a number of products of biological and pathophysiological significance (Table 2). There are known genetic deficiencies of most individual C complement components, but C3 deficiency is most serious and fatal. Complement deficiencies also occur in immune complex diseases (e.g., SLE) and acute and chronic bacterial, viral and parasitic infections.
|
||||||||||||||||||||||||||||||||||||||||||||||||
You have learned The proteins of the complement system The differences and similarities among the different pathways of C3 activation The significance of the different pathways in specific and nonspecific immunity The role of different complement activation products in amplification of nonspecific and specific immunity and inflammation |
|
||||||||||||||||||||||||||||||||||||||||||||||||
Return to the Department of Microbiology and Immunology Site Guide Return to the Immunology Section of Microbiology and Immunology On-line This page copyright
2004, The Board of
Trustees of the University of South Carolina |